Chinese Japanese Germany Korea
ChemicalBook >> CAS DataBase List >>Minocycline hydrochloride

Minocycline hydrochloride

Minocycline hydrochloride Structure
Minocycline hydrochloride structure
CAS No.
13614-98-7
Chemical Name:
Minocycline hydrochloride
Synonyms
MINOCYCLINE HCL;Arestin;Dynacin;minocyclinechloride;[4S-(4alpha,4aalpha,5aalpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide monohydrochloride;minocyn;MINOCIN;tri-mino;MYNOCINE;Minomycin
CBNumber:
CB6472139
Molecular Formula:
C23H28ClN3O7
Molecular Weight:
493.94
MDL Number:
MFCD00083669
MOL File:
13614-98-7.mol
MSDS File:
SDS
TDS File:
TDS
Last updated:2026-08-20 20:20:01
Request For Quotation

Minocycline hydrochloride Properties

Melting point 205-210° (dec)
Boiling point 813℃
Flash point >110°(230°F)
storage temp. 2-8°C
solubility Sparingly soluble in water, slightly soluble in ethanol (96 per cent). It dissolves in solutions of alkali hydroxides and carbonates.
form crystalline
color yellow
Water Solubility Freely soluble in water
Merck 14,6202
Stability Light Sensitive
InChIKey GLMUAFMGXXHGLU-VQAITOIOSA-N
SMILES [C@@]12([H])C[C@@]3([H])C(C(=O)C4C(O)=CC=C(N(C)C)C=4C3)=C(O)[C@]1(O)C(=O)C(C(=O)N)=C(O)[C@H]2N(C)C.Cl |&1:0,3,21,31,r|
LogP 0.808 (est)
CAS DataBase Reference 13614-98-7(CAS DataBase Reference)
EWG's Food Scores 1
FDA UNII 0020414E5U
Proposition 65 List Minocycline Hydrochloride (internal use)
NCI Drug Dictionary Dynacin
UNSPSC Code 12352200
NACRES NA.77

SAFETY

Risk and Safety Statements

Symbol(GHS)  Exclamation Mark (GHS07)Health Hazard (GHS08)
GHS07,GHS08
Signal word  Danger
Hazard statements  H317-H360-H362-H303-H315-H319-H335
Precautionary statements  P201-P202-P260-P263-P264-P270-P272-P280-P302+P352+P333+P313+P363-P308+P313-P405-P501-P261-P280a-P304+P340-P305+P351+P338-P501a
PPE dust mask type N95 (US), Eyeshields, Gloves
Hazard Codes  Xi
Risk Statements  36/37/38
Safety Statements  26-36
RIDADR  3249
WGK Germany  3
RTECS  QI7630500
HazardClass  6.1(b)
PackingGroup  III
HS Code  29413020
Storage Class 11 - Combustible Solids
Toxicity human,TDLo,oral,14286ug/kg/10 (14.286mg/kg),LUNGS, THORAX, OR RESPIRATION: RESPIRATORY OBSTRUCTIONLUNGS, THORAX, OR RESPIRATION: DYSPNEASKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE",Archives of Internal Medicine. Vol. 154, Pg. 1633, 1994.
REACH Registrations Active
NFPA 704
0
2 0

Minocycline hydrochloride price More Price(84)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich 1444004 Minocycline hydrochloride United States Pharmacopeia (USP) Reference Standard 13614-98-7 350mg $455 2026-04-30 Buy
TCI Chemical M2288 Minocycline Hydrochloride >98.0%(HPLC)(T) 13614-98-7 1g $144 2026-04-30 Buy
TCI Chemical M2288 Minocycline Hydrochloride >98.0%(HPLC)(T) 13614-98-7 5g $488 2026-04-30 Buy
Cayman Chemical 14454 Minocycline (hydrochloride hydrate) ≥98% 25mg $44 2026-04-30 Buy
Cayman Chemical 14454 Minocycline (hydrochloride hydrate) ≥98% 50mg $75 2026-04-30 Buy
Product number Packaging Price Buy
1444004 350mg $455 Buy
M2288 1g $144 Buy
M2288 5g $488 Buy
14454 25mg $44 Buy
14454 50mg $75 Buy

Minocycline hydrochloride Chemical Properties, Uses, Production

Description

Minocycline HCl (13614-98-7) displays antiapoptotic, anti-inflammatory1 activity. Prevents neuropathic pain in a rat sciatic nerve injury model.1 Reduces MMP-9 activity.2 Attenuates disease severity in mouse models of multiple sclerosis.3 Displays neuroprotective activity.4 Minocycline HCl may be effective in methotrexate-induced lung fibrosis.5Orally active and brain penetrant.

Chemical Properties

Yellow Crystalline Powder

Originator

Minocin,Lederle ,US,1971

Uses

Second generation tetracycline antibiotic. Antibacterial.

Uses

antiinflammatory

Uses

Minocycline hydrochloride is a salt prepared from minocycline, taking advantage of the two basic dimethylamino groups which protonate and readily form a salt from hydrochloric acid solutions. The hydrochloride is the preferred formulation for pharmaceutical applications. Like all tetracyclines, minocycline shows broad spectrum antibacterial and antiprotozoan activity and acts by binding to the 30S and 50S ribosomal sub-units, blocking protein synthesis.

Manufacturing Process

Preparation of 7-(N,N'-Dicarbobenzyloxyhydrazino)-6-Demethyltetracycline: A1.0 g portion of 6-demethyltetracycline was dissolved in a mixture of 9.6 ml oftetrahydrofuran and 10.4 ml of methanesulfonic acid at -10°C. The mixturewas allowed to warm to 0°C. A solution of 0.86 g of dibenzyl azodicarboxylatein 0.5 ml of tetrahydrofuran was added dropwise and the mixture was stirredfor 2 hours while the temperature was maintained at 0°C. The reactionmixture was added to ether. The product was filtered off, washed with etherand then dried. The 7-(N,N'-dicarbobenzyloxyhydrazino)-6-demethyltetracycline was identified by paper chromatography.
Reductive Methylation of 7-(N,N'-Dicarbobenzyloxyhydrazino)-6-Demethyl-6-Deoxytetracycline to 7-Dimethylamino-6-Demethyl-6-Deoxytetracycline: Asolution of 100 mg of 7(N,N'-dicarbobenzyloxyhydrazino)-6-demethyl-6-deoxytetracycline in 2.6 ml of methanol, 0.4 ml of 40% aqueous ormaldehyde solution and 50 mg of 5% palladium on carbon catalyst washydrogenated at room temperature and two atmospheres pressure. Uptake ofthe hydrogen was complete in 3 hours. The catalyst was filtered off and thesolution was taken to dryness under reduced pressure. The residue wastriturated with ether and then identified as 7-dimethylamino-6-demethyl-6-deoxytetracycline by comparison with an authentic sample, according to USPatent 3,483,251.

brand name

Dynacin (Medicis); Minocin (Lederle); Minocin (Triax); Solodyn (Medicis).

Therapeutic Function

Antibiotic

General Description

Minocycline, 7-dimethylamino-6-demethyl-6-deoxytetracycline(Minocin, Vectrin), the most potent tetracycline currentlyused in therapy, is obtained by reductive methylationof 7-nitro-6-demethyl-6-deoxytetracycline. It was releasedfor use in the United States in 1971. Because minocycline,like doxycycline, lacks the 6-hydroxyl group, it is stablein acids and does not dehydrate or rearrange to anhydroor lactone forms. Minocycline is well absorbed orally togive high plasma and tissue levels. It has a very long serumhalf-life, resulting from slow urinary excretion and moderateprotein binding. Doxycycline and minocycline, alongwith oxytetracycline, show the least in vitro calcium bindingof the clinically available tetracyclines. The improved distributionproperties of the 6-deoxytetracyclines have been attributedto greater lipid solubility.
Perhaps the most outstanding property of minocyclineis its activity toward Gram-positive bacteria, especiallystaphylococci and streptococci. In fact, minocycline hasbeen effective against staphylococcal strains that are resistantto methicillin and all other tetracyclines, includingdoxycycline. Although it is doubtful that minocyclinewill replace bactericidal agents for the treatment of lifethreateningstaphylococcal infections, it may become auseful alternative for the treatment of less serious tissueinfections. Minocycline has been recommended for thetreatment of chronic bronchitis and other upper respiratorytract infections. Despite its relatively low renal clearance,partially compensated for by high serum and tissuelevels, it has been recommended for the treatment of urinary tract infections. It has been effective in the eradicationof N. meningitidis in asymptomatic carriers.

Biochem/physiol Actions

Minocycline is a broad spectrum antibiotic with bacteriostatic function. Minocycline has anti-inflammatory properties. Minocycline inhibits lipopolysaccharide mediated inflammatory cytokine tumour necrosis factor (TNF-α) secretion by macrophages. Minocycline inhibits macrophage proliferation in a dose dependent manner. Minocycline inhibits neuroinflammation in pre-plaque of Alzheimer′s disease-like amyloid pathology through inhibition of key inflammatory enzymes like inducible nitric oxide synthase (iNOS), matrix metalloproteinase 9 (MMP-9) and 5-lipoxygenase. Minocycline inhibits endothelial cell proliferation and angiogenesis. Minocycline exhibits anti-tumor activity in glioma by inhibiting membrane type 1 matrix metalloproteinase (MT1-MMP). Minocycline increases cognition and neuronal differentiation. zMinocycline effectively reduces neuropathic pain by increasing the functions of nociceptin/orphanin FQ.

Side effects

Common side effects of Minocycline hydrochloride include: nausea, vomiting, diarrhoea, dizziness, lightheadedness or spinning sensation. Individuals may experience symptoms of serious adverse reactions such as gingival hyperpigmentation, pain/difficulty swallowing, tinnitus or hearing loss, joint stiffness/pain/swelling, nephrotoxicity (elevated urea nitrogen, interstitial nephritis), hepatotoxicity (hyperbilirubinaemia, hepatic cholestasis, elevated liver enzymes, fatal hepatic failure, and jaundice), and hypersensitivity reactions. It rarely causes elevated pressure around the brain (intracranial hypertension - IH). The risk of this side effect is greater in women of childbearing age who are overweight or who have had IH in the past. Serious intestinal disorders including: non-stop diarrhoea, abdominal or stomach pain/cramps, and blood/mucus in the stool are less common.

Veterinary Drugs and Treatments

Minocycline may be useful for treating Brucellosis (in combination with aminoglycosides), Lyme disease, and certain nosocomial infections where other more commonly used drugs are ineffective. It has been investigated as adjunctive therapy for treating hemangiosarcomas, but early results have been disappointing.

storage

+4°C

References

[1] SATYANARAYANA S.V. PADI  Shrinivas K K. Minocycline prevents the development of neuropathic pain, but not acute pain: Possible anti-inflammatory and antioxidant mechanisms[J]. European journal of pharmacology, 2008, 601 1: Pages 79-87. DOI:10.1016/j.ejphar.2008.10.018
[2] MAGDALENA DZIEMBOWSKA. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline.[J]. American Journal of Medical Genetics Part A, 2013, 161A 8: 1897-1903. DOI:10.1002/ajmg.a.36023
[3] BRUNDULA V, REWCASTLE N, METZ L, et al. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis.[J]. Brain : a journal of neurology, 2002, 51 1: 0. DOI:10.1093/brain/awf133
[4] T. TIKKA. Minocycline, a Tetracycline Derivative, Is Neuroprotective against Excitotoxicity by Inhibiting Activation and Proliferation of Microglia[J]. The Journal of Neuroscience, 2001, 69 1: 2580-2588. DOI:10.1523/jneurosci.21-08-02580.2001
[5] S KALEMCI. The efficacy of minocycline against methotrexate-induced pulmonary fibrosis in mice.[J]. European review for medical and pharmacological sciences, 2013, 17 24: 3334-3340.

Minocycline hydrochloride synthesis

10118-90-8
13614-98-7
Synthesis of Minocycline hydrochloride from Minocycline

Minocycline hydrochloride Preparation Products And Raw materials

Raw materials

Minocycline demeclocycline hydrochloride,hemihydrate Demecycline Hydrogen Dibenzyl azodicarboxylate

Preparation Products

Minocycline hydrochloride Suppliers

Global Suppliers ( 670)
Supplier Tel Email Country ProdList Advantage
Nanjing Ally Chemical S&T Co., Ltd. 025-025-58367986 18913956109 amy.xiang@ally-chem.com China 662 58
Hubei widely chemical technology Co., Ltd. 027-83991130 18627774460 1718093273@QQ.COM China 1617 58
Suizhou HongQi Chemical Corporation Limited 0722-3257376 13026100080;13235518175; 774811011@qq.com China 60 55
Jiangxi ravel Biotechnology Co.,Ltd 18502728206 hj@ruiweier.cn China 2436 58
Hubei Hongyun long biological technology Co. Ltd. 13554337556 13554337556 342063746@qq.com China 2175 58
Beijing Hope International Pharmaceutical Technology Development Co., Ltd 01067886402 15600038801 wuhangjin@hopelife.cn China 19 58
Hunan ravel Biotechnology Co.,Ltd 18627957289 18173226957 3628571360@qq.com China 3000 58
J & K SCIENTIFIC LTD. 18210857532 18210857532 jkinfo@jkchemical.com China 96815 76
Meryer (Shanghai) Chemical Technology Co., Ltd. 4006356688 18621169109 market03@meryer.com China 40202 62
3B Pharmachem (Wuhan) International Co.,Ltd. 18930552037 3bsc@sina.com China 15813 69
Supplier Advantage
Nanjing Ally Chemical S&T Co., Ltd. 58
Hubei widely chemical technology Co., Ltd. 58
Suizhou HongQi Chemical Corporation Limited 55
Jiangxi ravel Biotechnology Co.,Ltd 58
Hubei Hongyun long biological technology Co. Ltd. 58
Beijing Hope International Pharmaceutical Technology Development Co., Ltd 58
Hunan ravel Biotechnology Co.,Ltd 58
J & K SCIENTIFIC LTD. 76
Meryer (Shanghai) Chemical Technology Co., Ltd. 62
3B Pharmachem (Wuhan) International Co.,Ltd. 69

Related articles

View Latest Price from Minocycline hydrochloride manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Minocycline hydrochloride pictures 2026-09-17 Minocycline hydrochloride
13614-98-7
 0.99 RongNa Biotechnology Co.,Ltd
Minocycline hydrochloride pictures 2026-09-17 Minocycline hydrochloride
13614-98-7
 100g 890-950ug/mg; USP41 400kg/month WUHAN FORTUNA CHEMICAL CO., LTD
Minocycline HCl pictures 2026-09-01 Minocycline HCl
13614-98-7
 1kg 99% 10000kg Shaanxi TNJONE Pharmaceutical Co., Ltd

Minocycline hydrochloride Spectrum

Minocycline hydrochloride(13614-98-7)1HNMRMinocycline hydrochloride(13614-98-7)IRMinocycline hydrochloride(13614-98-7)Raman

13614-98-7 (Minocycline hydrochloride) Related Search:

Venlafaxine hydrochloride NU1025 Minocycline Impurity 9 7-Didemethyl Minocycline Dihydrochloride (>85% by HPLC) Starch
Penicillin G sodium salt Tilmicosin phosphate Ciprofloxacin hydrochloride Erythromycin thiocyanate 2-Pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-N-(4-fluorophenyl)-5,6-dimethyl-, monohydrochloride
8-Azabicyclo[3.2.1]octane, 3-chloro-8-methyl- Fisetin Naringenin Zoledronic acid Veliparib
RG108 Forskolin Mianserin hydrochloride

1of4

KlinoMycin, Minocycline chloride, MinoMycin, NSC 141993 (4S,4aS,5aR,12aS)-4,7-Bis(diMethylaMino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxaMide hydrochloride 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, hydrochloride (1:1), (4S,4aS,5aR,12aS)- Minocycline hydrochloride Solution, 100ppm Minocycline hydrochloride, >=98% [4S-(4alpha,4aalpha,5aalpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-te 10,12,12a-tetrahydroxy-1,11-dioxo--monohydrochloride 2-(Amino-hydroxy-methylidene)-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4,4a,5,5a,6,12a-hexahydrotetracene-1,3,12-trione hydrochloride minocyclinechloride minocyclinehydrochloridehydrate minocyn 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, monohydrochloride, (4S,4aS,5aR,12aS)- 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, monohydrochloride (8CI) 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, monohydrochloride, (4S,4aS,5aR,12aS)- (9CI) 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, monohydrochloride, [4S-(4a,4aa,5aa,12aa)]- Klinomycin minocyline hydrochloride Minomycin NSC 141993 Periocline 7-Dimethylamino-6-demethyl-6-deoxytetracyline [4S-(4alpha,4aalpha,5aalpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide monohydrochloride Coupelacin Minostacin Periofeel [4S-(4α,4aα,5aα,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a,tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide Minocycline Hydrochloride (200 mg) Minocycline Hydrochloride (350 mg) Minoxycline tri-mino tri-minocycline MYNOCINE MINOCYCLINE HYDROCHLORIDE MINOCIN Minocyclinhydrochloride 7-DIMETHYLAMINO-6-DEMETHYL-6-DEOXYTETRACYCLINE, HCL 7-DIMETHYLAMINO-6-DEMETHYL-6-DEOXYTETRACYCLINE HYDROCHLORIDE [4S-(4a,4aa,5aa,12aa)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydro-1,11-dioxo-2-naphthacenecarboxamide Hydrochloride Arestin Dynacin Klinomyci [4S-(4α,4aα,5aα,12aα)]-4,7-Bis(diMethylaMino)-1,4,4a,5,5a,6,11,12a -octahydro-3,10,12,12a-tetrahydro-1,11-dioxo-2-naphthacenecarboxaMide Hydrochloride Minocycline, Minocycline Hcl 10,12,12a-tetrahydroxy-1,11-dioxo-- KlinoMycin, Minocycline chloride Minocycline Hydrochloride Pack:150G X 2 Minocycillin 2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione hydrochloride Minocycline, Hydrochloride - CAS 13614-98-7 - Calbiochem Omadacycline intermediate Minocycline hydrochloride salt MinocyclineHydrochloride> Minocycline hydrochloride CRS [4S-(4α,4aα,5aα,12aα)]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide monohydrochloride Minocycline hydrochloride USP/EP/BP Minocycline Hydrochloride DihydrateV Minocycline hydrochloride / Minocycline hcl Minocycline hydrochl